[Effective cetuximab monotherapy for a case of recurrence rectal cancer after multiple previous chemotherapy treatment (FOLFOX, FOLFIRI)].
Cetuximab is an agent approved as epidermal growth factor receptor (EGFR)-positive for unresectable advanced or recurrent colorectal cancer. A 58-year-old man with liver metastasis had relapsed after resection of rectal cancer. We treated him with cetuximab monotherapy as third-line chemotherapy after treatment failures with infusional 5-FU, LV and oxaliplatin (FOLFOX4 regi- men); and infusional 5-FU, LV and irinotecan(FOLFIRI regimen). The patient was administered cetuximab (400 mg/m² initial dose and 250 mg/m²/ week thereafter). After sixteen weeks of treatment, a computed tomography scan revealed reduced sizes of the liver metastases. The tumor response has still been maintained after thirty courses of treatment, and the chemotherapeutic response was evaluated as a partial response according to the Response Evaluation Criteria In Solid Tumor guidelines. The main toxicity was a grade 2 rash, but was manageable by topical steroid and moisturizing agent. We have added some review of the literature, and the cetuximab therapy is reported.